$BABY (Natus Medical Inc.)

$BABY {{ '2016-10-19T16:20:34+0000' | timeago}} • Announcement

$BABY, the maker of medical device for newborn care, reported a rise in 3Q16 earnings driven by lower provision for income tax expense, despite a fall in revenue. Net income rose to $13.16MM or $0.40 per share from $10.93MM or $0.33 per share last year. Revenue fell to $90.91MM from $94.58MM. Non-GAAP EPS was flat with last year at $0.39.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$VAR {{ '2017-07-11T12:14:17+0000' | timeago}} • Announcement

$VAR begins advanced breast cancer treatments using Edge radiosurgery system in combination with respiratory gating. The Edge radiosurgery system enables clinicians to attack tumors from outside the body using carefully shaped high-energy X-rays.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MTD {{ '2017-07-05T13:49:43+0000' | timeago}} • Announcement

$MTD said Elisha Finney has been appointed to its BoD and Audit Committee, effective November 1, 2017. It is anticipated that Finney will succeed Francis Contino as the Chair of the Audit Committee upon his retirement in May 2018. Finney served as the CFO of $VAR.

$MASI {{ '2017-06-30T12:41:36+0000' | timeago}} • Announcement

Medical technology firm $MASI entered into a partnership with Midmark Corp. for enhancing the accuracy and efficiency of vital signs acquisition in the clinical space. Under the deal, Masimo’s SET pulse oximetry technology is an available option with Midmark's IQvitals Zone. The combination provides accurate and real-time vital signs information.

$VAR {{ '2017-06-29T13:48:54+0000' | timeago}} • Announcement

$VAR has received both FDA 510(k) clearance and CE mark for its Halcyon system, the company's new device for cancer treatment.

$VAR {{ '2017-06-29T13:28:06+0000' | timeago}} • Announcement

$VAR said it received FDA clearance for its cancer treatment device Halcyon, which enhances image-guided volumetric intensity modulated radiotherapy. The system is designed to accelerate installation timeframes, expedite commissioning and automate treatment.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$VAR {{ '2017-06-22T15:41:36+0000' | timeago}} • Announcement

$VAR delivered the cyclotron, a particle accelerator which accelerates protons to two-thirds the speed of light for clinical use, to UK's Christie Proton Therapy Center.

$VAR {{ '2017-06-21T12:39:55+0000' | timeago}} • Announcement

$VAR said it is working with Sify Technologies to provide software-as-a-service (SaaS) to radiotherapy centers across India. The innovative service is being implemented as part of a multi-million dollar investment in treatment equipment and software across Cancer Treatment Services International network of cancer hospitals in India and South Asia.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

Recent Transcripts

NURO (NeuroMetrix Inc.)
Thursday, July 20 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ETRM (EnteroMedics Inc.)
Tuesday, May 16 2017 - 12:30pm
RMTI (Rockwell Medical, Inc.)
Tuesday, May 9 2017 - 8:30pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, April 26 2017 - 9:00pm
BABY (Natus Medical Inc.)
Wednesday, April 26 2017 - 3:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
NURO (NeuroMetrix Inc.)
Thursday, April 20 2017 - 12:00pm
RMTI (Rockwell Medical, Inc.)
Wednesday, March 15 2017 - 8:30pm
ETRM (EnteroMedics Inc.)
Tuesday, March 7 2017 - 4:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like